Topic archive
MedTech Current publications and recall entries tagged AI & Algorithms.
FDA's October 20 update highlights hypothetical pathways for hospital-specific sepsis models and automated ECG model retraining. The examples connect planned changes with validation, controlled deployment and continued oversight, without authorizing unrestricted learning.
The TGA has completed its review of the conditional exclusion for certain digital mental health tools, finding that the criteria may allow higher-risk products to remain outside its oversight. Public consultation on regulatory options is planned for 2026; the update does not establish a final replacement rule or commencement date.
The TGA's review identifies potentially regulated functions in eight of 12 digital scribes. Intended purpose, clinical outputs and conditional CDSS exemptions determine the applicable regulatory position.
MHRA plans an adaptive framework for AI medical devices, a Centre for AI and Digital Health, and stronger lifecycle data and traceability. The 14 October strategy sets future priorities; planned UDI measures remain subject to the parliamentary process.
PMDA has made its September draft review points for generative AI medical devices available in English. The draft discusses clinical scope, performance testing, supplier dependencies and life-cycle risk management; the translation introduces no newly effective requirements.
The US FDA has issued a final order denying an industry petition seeking partial 510(k) premarket notification exemptions for radiology CADe, CADx, and CADt software devices under 21 CFR Part 892.
The Russian Ministry of Health has enacted Order No. 421n, replacing Order No. 885n to establish updated rules for technical testing, toxicological evaluation, and clinical investigations for state registration.
The US FDA has issued a final order codifying cardiovascular machine learning-based notification software under 21 CFR 870.2380 as Class II (special controls), establishing a 510(k) pathway while excluding arrhythmia detection.
The 25 August 2026 update to the UK AI Research Resource page only adds AMD to the partner list; it does not introduce a new AI or digital-health regulatory requirement. For healthcare AI and R&D teams, the more important opportunity is the existing access to Isambard-AI and Dawn through routes such as Rapid Access and Gateway.
FDA has issued a discussion paper seeking feedback on how generative AI-enabled medical devices should be assessed across risk classification, premarket evaluation, and postmarket monitoring. The paper outlines possible approaches including a two-axis risk framework and competency-based premarket assessment, but it does not establish new regulatory requirements.